PANLIN Capital Hosts Biopharma Portfolio Empowerment Forum: 'Achieving Premium Vitality! Diversified Development Pathways for China's Innovative Biopharma Companies'

May 10,Panlin Capital Biomedical Investment Post-Empowerment Special Forum——“Achieving High-Quality Vitality! The Diversified Development Path of China's Innovative Pharmaceutical Enterprises"Successfully held. This isPanlin CapitalUnitedVCBeatDuring the "2025 VBEF Future Healthcare 100 Exhibition"In-depth Seminar Planned by Panlin Portfolio, and invited founders of relevant companies, senior investors, and strategic leaders of multinational pharmaceutical enterprises to attend the event. They will discuss topics such as independent innovation and global development in China's innovative drug industry.

As the organizer,Li Yuhui, Founding Managing Partner of Panlin CapitalExpress welcome to the arriving guests and also to the co-organizers.VCBeatAnd supporting unitsRehabilitation CapitalExpressed gratitude. He stated that the forum organized by Panlin is based on a critical "tipping point" in the development of China's innovative drug industry, hoping to explore high-quality development paths for Chinese innovative pharmaceutical companies in an era of uncertainty together with outstanding founders and venture capital professionals from the medical industry, especially those involved in innovative drug research and development. He also noted that despite the recent capital winter faced by the biopharmaceutical industry, innovations continue to emerge, and the industry is thriving.The Clinical Value and Commercial Boundaries of China's Innovative Drugs Continue to Expand. This, together with the cold spell in the capital market, constitutes aScissors Gap. From an investment perspective,Now is the best time to invest in biomedicine.。

Founding Managing Partner of Panlin Capital, Li Yuhui

Professor Zicai Liang, Founder of Ribo Life SciencePublished an article titled "Global Trends in the Small Nucleic Acid Pharmaceutical Industry – Ribo Life Science's International Layout"Professor Liang pointed out in his speech that 'Small nucleic acid drugs have tremendous advantages in high drugability, rapid R&D speed, and ultra-long efficacy, bringing about a revolution in the modern pharmaceutical field and forming the third wave of modern pharmaceuticals. The next 10 to 20 years will be the golden period for small nucleic acid drug R&D. China has already established a globally competitive research and development foundation in the field of small nucleic acid drugs. In this strategic emerging field, our country has the opportunity to build an "electric vehicle-style" lane-changing and overtaking advantage.'"

Founder of Ribo Life Science, Professor Zicai Liang

Professor Cheng Xin, Founder of EndoCellPublished a paper titled "Tissue Replacement Therapy Paradigm —— Regenerative Islet Transplantation for Curing Diabetes"The theme speech. He pointed out that 'EndoCell's regenerated islets prepared using endodermal stem cell technology have achieved positive results in curing Type II and Type I diabetes in both autologous and allogeneic IIT patients. EndoCell's ultimate goal is to become a pioneer and leader in the field of tissue and organ regeneration by curing diseases through natural methods.'"

Founder of EndoCell, Professor Cheng Xin

Moreover, for the presentThe innovative drug forms and development pathways continuously explored by China's innovative pharmaceutical companies, Panlin Capital also collaborated with its invested companies respectively on "China's Innovative Pharmaceutical Companies BD Gains Momentum”、“How Domestic CGT Moves Towards Commercialization" and other topics for in-depth discussion.

In "BD Momentum: China's Innovative Pharmaceutical Companies Continue to Unlock Greater Value"In the roundtable discussion, the guests unanimously believed that,BD has become one of the important ways for China's innovative pharmaceutical companies to obtain cash flow, accelerate pipeline progress, and even achieve profitability.. In the process of advancing BD cooperation, China's innovative pharmaceutical companies must have"Open and Win-Win"The mentality, and take the initiative to connect cooperative resources。And a successful deal should also have the effect ofWin-Win, which is also the key for the product to continue moving forward.。

In "Growing Pains: Challenges and Responses in the Commercialization Process of China's CGT Industry"In the roundtable discussion, the guests discussed products related to the CGT field.Commercialization prospects are optimistic,BelieveIn the next 3-5 years, products from Chinese pharmaceutical companies will be approved for marketing in related细分 fields.. It was also pointed out that the premise of commercialization isMaking Good MedicineCome, and then integrate through various measures and systems.Gradually reduce the cost. From the perspective of each company's product development strategy, everyone isLayout their product lines based on clinical needs and commercial feasibility.。